An elevated tumor mutational burden (TMB) in the blood has now demonstrated its potential as a reliable clinical biomarker for predicting the clinical efficacy of the checkpoint inhibitor Tecentriq (atezolizumab, Roche Holding AG) in treating patients with advanced non-small-cell lung cancer (NSCLC), a Sino-U.S. study has shown.